Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03580655 · OUTCOME

Percent Change From Baseline in Serum Tryptase

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis · Source last updated 2026-04-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
Percent Change
Interval / dispersion
Standard Deviation
Time frame
Baseline up to Month 65

What was measured

Blood samples were collected to characterize the change in serum tryptase concentration during treatment with avapritinib. Each cycle is 28 days long.

Analysis population: Safety Population: all participants who received ≥1 dose of avapritinib. Here, 'Number Analyzed' signifies those participants evaluable for this outcome measure at the specified timepoint.

Groups in this outcome

Avapritinib

Avapritinib was administered once daily as an immediate-release tablet, orally, in 28-day cycles.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Avapritinib98

Reported measurements

Cycle 1, Day 15

Analysis denominator · Participants

GroupSource count
Avapritinib98
Values in Percent Change · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Avapritinib-64.5441.191Not reportedNot reportedNot reported
Cycle 2, Day 1

Analysis denominator · Participants

GroupSource count
Avapritinib96
Values in Percent Change · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Avapritinib-68.5442.091Not reportedNot reportedNot reported
Cycle 3, Day 1

Analysis denominator · Participants

GroupSource count
Avapritinib89
Values in Percent Change · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Avapritinib-71.7640.023Not reportedNot reportedNot reported
Cycle 7, Day 1

Analysis denominator · Participants

GroupSource count
Avapritinib75
Values in Percent Change · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Avapritinib-75.1845.822Not reportedNot reportedNot reported
Cycle 11, Day 1

Analysis denominator · Participants

GroupSource count
Avapritinib77
Values in Percent Change · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Avapritinib-78.6936.038Not reportedNot reportedNot reported
Cycle 17, Day 1

Analysis denominator · Participants

GroupSource count
Avapritinib67
Values in Percent Change · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Avapritinib-85.2226.070Not reportedNot reportedNot reported
Cycle 23, Day 1

Analysis denominator · Participants

GroupSource count
Avapritinib58
Values in Percent Change · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Avapritinib-85.6130.510Not reportedNot reportedNot reported
Cycle 29, Day 1

Analysis denominator · Participants

GroupSource count
Avapritinib48
Values in Percent Change · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Avapritinib-83.5040.716Not reportedNot reportedNot reported
Cycle 35, Day 1

Analysis denominator · Participants

GroupSource count
Avapritinib43
Values in Percent Change · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Avapritinib-83.3945.603Not reportedNot reportedNot reported
Cycle 41, Day 1

Analysis denominator · Participants

GroupSource count
Avapritinib40
Values in Percent Change · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Avapritinib-90.6414.206Not reportedNot reportedNot reported
Cycle 47, Day 1

Analysis denominator · Participants

GroupSource count
Avapritinib33
Values in Percent Change · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Avapritinib-90.6412.581Not reportedNot reportedNot reported
Cycle 53, Day 1

Analysis denominator · Participants

GroupSource count
Avapritinib25
Values in Percent Change · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Avapritinib-68.6585.482Not reportedNot reportedNot reported
Cycle 59, Day 1

Analysis denominator · Participants

GroupSource count
Avapritinib13
Values in Percent Change · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Avapritinib-92.236.8211Not reportedNot reportedNot reported
Cycle 65, Day 1

Analysis denominator · Participants

GroupSource count
Avapritinib5
Values in Percent Change · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Avapritinib-82.0114.529Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        41.191
        value
        -64.54
    denoms
    1. counts
      1. group Id
        OG000
        value
        98
      units
      Participants
    title
    Cycle 1, Day 15
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        42.091
        value
        -68.54
    denoms
    1. counts
      1. group Id
        OG000
        value
        96
      units
      Participants
    title
    Cycle 2, Day 1
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        40.023
        value
        -71.76
    denoms
    1. counts
      1. group Id
        OG000
        value
        89
      units
      Participants
    title
    Cycle 3, Day 1
  4. categories
    1. measurements
      1. group Id
        OG000
        spread
        45.822
        value
        -75.18
    denoms
    1. counts
      1. group Id
        OG000
        value
        75
      units
      Participants
    title
    Cycle 7, Day 1
  5. categories
    1. measurements
      1. group Id
        OG000
        spread
        36.038
        value
        -78.69
    denoms
    1. counts
      1. group Id
        OG000
        value
        77
      units
      Participants
    title
    Cycle 11, Day 1
  6. categories
    1. measurements
      1. group Id
        OG000
        spread
        26.070
        value
        -85.22
    denoms
    1. counts
      1. group Id
        OG000
        value
        67
      units
      Participants
    title
    Cycle 17, Day 1
  7. categories
    1. measurements
      1. group Id
        OG000
        spread
        30.510
        value
        -85.61
    denoms
    1. counts
      1. group Id
        OG000
        value
        58
      units
      Participants
    title
    Cycle 23, Day 1
  8. categories
    1. measurements
      1. group Id
        OG000
        spread
        40.716
        value
        -83.50
    denoms
    1. counts
      1. group Id
        OG000
        value
        48
      units
      Participants
    title
    Cycle 29, Day 1
  9. categories
    1. measurements
      1. group Id
        OG000
        spread
        45.603
        value
        -83.39
    denoms
    1. counts
      1. group Id
        OG000
        value
        43
      units
      Participants
    title
    Cycle 35, Day 1
  10. categories
    1. measurements
      1. group Id
        OG000
        spread
        14.206
        value
        -90.64
    denoms
    1. counts
      1. group Id
        OG000
        value
        40
      units
      Participants
    title
    Cycle 41, Day 1
  11. categories
    1. measurements
      1. group Id
        OG000
        spread
        12.581
        value
        -90.64
    denoms
    1. counts
      1. group Id
        OG000
        value
        33
      units
      Participants
    title
    Cycle 47, Day 1
  12. categories
    1. measurements
      1. group Id
        OG000
        spread
        85.482
        value
        -68.65
    denoms
    1. counts
      1. group Id
        OG000
        value
        25
      units
      Participants
    title
    Cycle 53, Day 1
denoms
  1. counts
    1. group Id
      OG000
      value
      98
    units
    Participants
description
Blood samples were collected to characterize the change in serum tryptase concentration during treatment with avapritinib. Each cycle is 28 days long.
dispersion Type
Standard Deviation
groups
  1. description
    Avapritinib was administered once daily as an immediate-release tablet, orally, in 28-day cycles.
    id
    OG000
    title
    Avapritinib
param Type
MEAN
population Description
Safety Population: all participants who received ≥1 dose of avapritinib. Here, 'Number Analyzed' signifies those participants evaluable for this outcome measure at the specified timepoint.
reporting Status
POSTED
time Frame
Baseline up to Month 65
title
Percent Change From Baseline in Serum Tryptase
type
SECONDARY
unit Of Measure
Percent Change

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice